SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic Burden of Haematological Adverse Effects in Cancer Patients
1 references·1 citing·10 second hop
Economic Burden of Haematological Adverse Effects in Cancer Patients (2007)Economic Burden of Haematological Adverse…Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer (2006)Frequency and Cost of Chemoth…Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma (2018)Cost-effectiveness of nivolum…Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. (2001)External validity of randomised controlled trials: “To whom do the results of this trial apply?” (2005)HealtH ReseaRcH Data foR tHe Real WoRlD: tHe MaRketscan ® Databases (2008)How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment (2010)The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue (2013)Model Parameter Estimation and Uncertainty Analysis (2012)Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 (2016)Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non–Small Cell Lung Cancer (2021)Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021)
this work references cited by second hop

References

  • 2006Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer360 cited

Cited by

  • 2018Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma120 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work